Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody.
Lantheus Holdings, Inc.
Unlock to Claim this listing
Add / Modify Company
3.1
Overall Excellence Rating
Industry
HealthcareCategory
Diagnostics & ResearchESG/Ethical Impact
Our industry functions within a global ecosystem and we know that our actions must preserve and protect the environment. Sustainability is at the forefront of everything we do. In 2022, we made measurable improvements in water usage, waste management and energy consumption: 12.2% reduction in water usage over 4 years (2019–2022), 16.7% waste reduction over 3 years (2020–2022), 37.3% reduction in greenhouse gas emissions over 4 years (2019–2022)We embrace diversity and inclusion as a core component of our culture. And we actively promote these ideals at every level. In 2021, we sponsored two new Employee Resource Groups (ERGs), the Lantheus Diversity Connection ERG and Women Leaders of Lantheus ERG. In our hiring practices, we work closely with recruiters to ensure that we’re seeing diverse candidates and we continually focus on pay equity for all employees. Our procurement teams also place an emphasis on partnering with minority-owned, female-owned and other diverse businesses and organizations. Our corporate culture is one of ethics, integrity and transparency. From mandatory training on business practices to accuracy in financial reporting, we remain committed to principles of behavior that meet the highest standards—and those of our formal Ethics and Compliance Committee. We also maintain codes of conduct with our suppliers to ensure they’re operating in a legal, ethical and socially responsible manner.Our commitment to corporate social responsibility is rooted in the belief that we can always do more for our patients, our people and our planet. And it’s reflected in the many initiatives we undertake and activities we sponsor to make a positive impact on our environment, workplace and community. Because we go further when we work together.Our commitment to equity and inclusion is also reflected in our employee benefits, including a hybrid work environment, competitive compensation, 401(k) matching, education assistance and equity grants at certain levels.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Awards Received
2023
Revenues
$935,000,000.00
Website Traffic
Employee Rating
3.2
Customer Rating
3.1
Company Size
100-1000
ESG Risk Rating
2